June 03, 2019
OSLO, Norway, June 3, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a...
Source URL: https://prnmedia.prnewswire.com:443/news-releases/targovax-announces-publication-of-in-vivo-abscopal-effect-of-oncos-102-and-keytruda-combination-300860388.html
|
